The delivery of nanovaccines containing cytosine-guanine oligodeoxynucleotides, STAT3 siRNA, and tumor-specific antigens to DCs significantly enhanced the CD8+ T cell responses and inhibited tumor growth [85]. The gene discussed is STAT3; the disease is neoplasm.